Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer.
Chemotherapy
Clinical complete response
Gastric cancer
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
07
04
2020
accepted:
07
04
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Gastric cancer incidence is high in several countries, and management of advanced gastric cancer remains a challenge. Chemotherapy for unresectable gastric cancers is still evolving, and achieving a complete cure is difficult. Although a clinical complete response to chemotherapy has been reported in patients with unresectable gastric cancer, the chemotherapy duration for these patients is unclear. Here, we report the case of a 71-year-old man who presented with abdominal discomfort. Upper endoscopy revealed advanced gastric cancer on the upper gastric body. Histopathological examination revealed a poorly differentiated adenocarcinoma. Computed tomography revealed regional lymph node and multiple bilobar hepatic metastases. Radical surgery was not possible; therefore, palliative resection of the primary lesion was planned for symptomatic improvement. Tegafur, 5-chloro-2,4-dihydro-pyrimidine, and potassium oxonate were administered prior to surgery, and proximal gastrectomy was performed. Tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate administration was reinitiated after surgery. A clinical complete response was achieved in the 8th postoperative month, with no hepatic metastases noted on radio imaging. Computed tomography performed in the 1st postoperative year revealed ascites; however, the cytological examination findings were negative. The initial chemotherapy was discontinued, and paclitaxel administration was commenced. Computed tomography performed annually thereafter demonstrated no recurrence, and paclitaxel was discontinued in the 9th postoperative year. The patient remained recurrence free at 12 years postoperatively. For elderly patients like the one presented here, it may be necessary to consider ceasing chemotherapy; however, because it is possible for a complete clinical response over the long term, it should be continued if the patient is well.
Identifiants
pubmed: 32774258
doi: 10.1159/000507781
pii: cro-0013-0689
pmc: PMC7383153
doi:
Types de publication
Case Reports
Langues
eng
Pagination
689-695Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Gastric Cancer. 2011 Oct;14(4):301-16
pubmed: 21894577
J Clin Oncol. 2003 Jan 1;21(1):54-9
pubmed: 12506170
Lancet Oncol. 2009 Nov;10(11):1063-9
pubmed: 19818685
Gastric Cancer. 1998 Dec;1(1):10-24
pubmed: 11957040
World J Surg Oncol. 2015 Sep 04;13:268
pubmed: 26336890
Gastric Cancer. 2003;6 Suppl 1:9-12
pubmed: 12775013
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
Eur J Cancer. 2010 Mar;46(4):765-81
pubmed: 20116997
Gastric Cancer. 2012 Jul;15(3):305-12
pubmed: 22160244
J Nippon Med Sch. 2016;83(5):199-202
pubmed: 27890894
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
Gastric Cancer. 2003;6 Suppl 1:19-23
pubmed: 12775015
Oncology. 2013;85(5):262-8
pubmed: 24192723
Gastric Cancer. 2006;9(1):14-8
pubmed: 16557431